Hydroxyurea in the treatment of neoplasms of the head and neck. A resurvey.
D000284:Administration, Oral; D004428:Ear Neoplasms / Q000188:drug therapy* / Q000401:mortality; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007822:Laryngeal Neoplasms / Q000188:drug therapy* / Q000401:mortality; D009060:Mouth Floor; D009062:Mouth Neoplasms / Q000188:drug therapy* / Q000401:mortality; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy* / Q000401:mortality; D009669:Nose Neoplasms / Q000188:drug therapy* / Q000401:mortality; D010157:Palatal Neoplasms / Q000188:drug therapy; D010255:Paranasal Sinus Neoplasms / Q000188:drug therapy* / Q000401:mortality; D010307:Parotid Neoplasms / Q000188:drug therapy*; D010610:Pharyngeal Neoplasms / Q000188:drug therapy* / Q000401:mortality; D011838:Radiation-Sensitizing Agents; D014062:Tongue Neoplasms / Q000188:drug therapy; D014067:Tonsillar Neoplasms / Q000188:drug therapy
D011838:Radiation-Sensitizing Agents; D006918:Hydroxyurea